Chang, Dorothy

68-year-old with ER+/HER2- invasive ductal carcinoma, Oncotype DX RS 26, 2/14 lymph nodes positive. Evaluate benefit of adjuvant chemotherapy in addition to endocrine therapy given intermediate recurrence score and limited nodal involvement.

68-year-old with ER+/HER2- invasive ductal carcinoma, Oncotype DX RS 26, 2/14 lymph nodes positive. Evaluate benefit of adjuvant chemotherapy in addition to endocrine therapy given intermediate recurrence score and limited nodal involvement. Consider TAILORx and RxPONDER trial data.

Restaging after neoadjuvant therapy — surgical timing and assessment of pathological response.

Optimal adjuvant endocrine therapy duration — 5 vs. 10 years of tamoxifen/AI given intermediate recurrence risk.

Oncotype DX recurrence score borderline — systemic chemotherapy benefit vs. endocrine therapy alone.

Consideration of ovarian suppression with AI in premenopausal patient with high-risk features.

Dose reduction strategy for AI-related arthralgia affecting treatment compliance.

Oncotype DX recurrence score borderline — systemic chemotherapy benefit vs. endocrine therapy alone.

Optimal adjuvant endocrine therapy duration — 5 vs. 10 years of tamoxifen/AI given intermediate recurrence risk.

Dose reduction strategy for AI-related arthralgia affecting treatment compliance.

Dose reduction strategy for AI-related arthralgia affecting treatment compliance.

Role of CDK4/6 inhibitor (abemaciclib) in adjuvant setting with high Ki-67 and node-positive disease.

Role of CDK4/6 inhibitor (abemaciclib) in adjuvant setting with high Ki-67 and node-positive disease.

Restaging after neoadjuvant therapy — surgical timing and assessment of pathological response.

Role of CDK4/6 inhibitor (abemaciclib) in adjuvant setting with high Ki-67 and node-positive disease.

Restaging after neoadjuvant therapy — surgical timing and assessment of pathological response.

Role of CDK4/6 inhibitor (abemaciclib) in adjuvant setting with high Ki-67 and node-positive disease.

Restaging after neoadjuvant therapy — surgical timing and assessment of pathological response.

Dose reduction strategy for AI-related arthralgia affecting treatment compliance.

Restaging after neoadjuvant therapy — surgical timing and assessment of pathological response.

Consideration of ovarian suppression with AI in premenopausal patient with high-risk features.

Restaging after neoadjuvant therapy — surgical timing and assessment of pathological response.

Consideration of ovarian suppression with AI in premenopausal patient with high-risk features.

Oncotype DX recurrence score borderline — systemic chemotherapy benefit vs. endocrine therapy alone.

Consideration of ovarian suppression with AI in premenopausal patient with high-risk features.

Optimal adjuvant endocrine therapy duration — 5 vs. 10 years of tamoxifen/AI given intermediate recurrence risk.

Restaging after neoadjuvant therapy — surgical timing and assessment of pathological response.

Oncotype DX recurrence score borderline — systemic chemotherapy benefit vs. endocrine therapy alone.

Dose reduction strategy for AI-related arthralgia affecting treatment compliance.

Oncotype DX recurrence score borderline — systemic chemotherapy benefit vs. endocrine therapy alone.